Philips and Celsion Receive FDA Go-ahead for Phase II Study of ThermoDox and MR-Guided HIFU in Bone Cancer


ANDOVER, MA and LAWRENCEVILLE, NJ — (Marketwire) — 08/07/12 — Royal Philips Electronics (NYSE: PHG) (AEX: PHI) and Celsion Corporation (NASDAQ: CLSN) today announced that the U.S. Food and Drug Administration (FDA) has provided clearance to initiate a clinical study supporting a joint development program for Celsion’s ThermoDox® combined with Philips’ Sonalleve MR-HIFU (MR-guided high intensity focused ultrasound) technology for the palliation of painful metastases to the bone caused by lung, prostate or breast cancers. The companies expect to initiate a Phase 2 study in this indication in the second half of 2012.